General Information of Drug (ID: DME9Y8Q)

Drug Name
AFD(R) Drug Info
Synonyms AFD(R); GTPL2937; CHEMBL382739; SCHEMBL12084862; Phosphoric acid (R)-2-methyl-2-amino-4-(4-heptyloxyphenyl)butyl ester; [(2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl] dihydrogen phosphate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10904818
TTD Drug ID
DME9Y8Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9522888, 575 DM6UXZK N. A. N. A. Patented [4]
US9617250, Example 1 Example 204 of D1 DM89LKQ N. A. N. A. Patented [5]
YYDJCLCSBYCSCO-UHFFFAOYSA-N DMA91FM N. A. N. A. Patented [6]
US9216972, 61 DM7AHQE N. A. N. A. Patented [7]
US9670220, 77 DMZG1HO N. A. N. A. Patented [8]
US10179791, Compound 296 DMLZBRM N. A. N. A. Patented [9]
JCXGHZCWAHCYGY-UHFFFAOYSA-N DMER7QX N. A. N. A. Patented [6]
US9216972, 67 DMXR5SZ N. A. N. A. Patented [7]
US10166249, Example 695 DMVMNP1 N. A. N. A. Patented [10]
US9181182, 40 DM3QIF4 N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Siponimod DM2R86O Multiple sclerosis 8A40 Approved [12]
Fingolimod DM5JVAN Multiple sclerosis 8A40 Approved [13]
Ozanimod DMT6AM2 Multiple sclerosis 8A40 Approved [14]
Etrasimod DMT0A3Y Ulcerative colitis DD71 Approved [15]
Ponesimod DMEAOYJ Multiple sclerosis 8A40 Approved [16]
MT-1303 DMSE9TH Crohn disease DD70 Phase 2 [17]
ONO-4641 DMLUM3Y Rheumatoid arthritis FA20 Phase 2 [18]
KRP-203 DMOW9X2 Cutaneous lupus erythematosus EB5Z Phase 2 [18]
VTX-002 DMZ8Z5A Ulcerative colitis DD71 Phase 2 [19]
CBP-307 DM3TH6Y Ulcerative colitis DD71 Phase 2 [20]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AUY954 DMVGIO5 Discovery agent N.A. Investigative [21]
FTY720-phosphate DMDZBQH Discovery agent N.A. Investigative [2]
VPC03090-P DMIXUM3 Discovery agent N.A. Investigative [22]
dihydrosphingosine-1-phosphate DM58KHY N. A. N. A. Investigative [23]
KRP 203-phosphate DMLIK7X Discovery agent N.A. Investigative [24]
phytosphingosine 1-phosphate DMWJCST Discovery agent N.A. Investigative [23]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ASP-4058 DM1RD0T Multiple sclerosis 8A40 Phase 1 [25]
AUY954 DMVGIO5 Discovery agent N.A. Investigative [21]
FTY720-phosphate DMDZBQH Discovery agent N.A. Investigative [26]
VPC03090-P DMIXUM3 Discovery agent N.A. Investigative [22]
VPC44116 DMQ4OTJ Discovery agent N.A. Investigative [27]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Agonist [2]
Sphingosine-1-phosphate receptor 3 (S1PR3) TTDYP7I S1PR3_HUMAN Agonist [2]
Sphingosine-1-phosphate receptor 4 (S1PR4) TTZ8C5Q S1PR4_HUMAN Agonist [3]
Sphingosine-1-phosphate receptor 5 (S1PR5) TTDZCKV S1PR5_HUMAN Agonist [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2937).
2 The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7.
3 Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48.
4 Substituted bicyclic compounds. US9522888.
5 Pyridin-4-yl derivatives. US9617250.
6 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519.
7 Tricyclic heterocyclic compounds. US9216972.
8 Fused heterocyclic derivatives as S1P modulators. US9670220.
9 Spiro-cyclic amine derivatives as S1P modulators. US10179791.
10 Substituted bicyclic compounds. US10166249.
11 S1P receptors modulators. US9181182.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
13 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
17 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
18 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
19 Clinical pipeline report, company report or official report of Ventyx Biosciences
20 Clinical pipeline report, company report or official report of Connect Biopharma
21 A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34.
22 Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89.
23 Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun. 2002 Sep 27;297(3):600-6.
24 A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-d... J Pharmacol Exp Ther. 2008 Jan;324(1):276-83.
25 ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
26 Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758-68.
27 Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77.